Compliance experts from Porzio Life Sciences, Edwards Lifesciences, Covidien and ReVision Optics tell an audience in Orange County how compliance pays for itself, not only in terms of security from regulatory headaches but as a boost to a company's valuation.
Compliance concerns may be driven largely by the desire to say out of the regulatory spotlight, but it's also a business strategy, a panel of experts told an audience during this week's MassDevice.com Big 100 West event in Orange County, Calif.
Covidien agrees to acquire Given Imaging for about $860 million in cash, sending Wall Street into a frenzy over GIVN shares.
Cook Medical rearranges its management, naming Rob Lyles as its new executive vice president.
Cook Medical named Rob Lyles executive vice president, the latest move in a larger management shift at the Indiana medtech maker.
Lyles was formerly vice president of Cook's peripheral intervention division. He has been with the company since 2003 and was named division VP in 2007. Lyles' promotion follows the advancement of Pete Yonkman to president of the Cook Medical. Mark Breedlove, a 19-year veteran of Cook Medical, will succeed Lyles as VP of the peripheral intervention division.
, CareFusion Corp.
, Cook Group Inc.
, Cook Medical
, IDEX Corp.
, Life Technologies Corp.
, Orthofix International
, Stryker Corp.
, Thermo Fisher Scientific
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Massachusetts medical device maker Covidien plans to open a new manufacturing facility in Hillsborough County, Fla., where the company expects to create 165 jobs and invest $18 million in capital by 2017.
MASSDEVICE ON CALL — Medical device maker Covidien (NYSE:COV) got a lot of praise from Florida regulators, who touted Covidien's plans to establish a new manufacturing facility that will be home to some 165 new workers.
Covidien's 4th-quarter and fiscal 2013 earnings beat expectations on low-single-digit sales growth.
Covidien (NYSE:COV) beat expectations on Wall Street with its 4th-quarter and fiscal 2013 earnings on sales growth in the low single digits for both periods.
Mansfield, Mass.-based Covidien posted profits of $372 million, or 80¢ per share, on sales of $2.56 billion for the 3 months ended Sept. 27.
Kardiametrics sues a raft of big-name medical device companies, including Boston Scientific, Abbott and Covidien, alleging infringement of its patents for blood clot protection devices.